| dbo:abstract
|
- Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment. T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor. The resulting chimeric antigen receptor T cells (CAR-Ts) that react to the cancer are then given back to the person to populate the bone marrow. Axicabtagene treatment carries a risk for cytokine release syndrome (CRS) and neurological toxicities. Due to CD19 being a pan-B cell marker, the T-cells that are engineered to target CD19 receptors on the cancerous B cells also influence normal B cells, except some plasma cells. (en)
- Axicabtagene ciloleucel, vendu sous le nom de marque Yescarta, est une thérapie (immunothérapie) ciblant deux types de lymphomes : 1.
* lymphome diffus à grandes cellules B (LDGCB) 2.
* lymphome médiastinal primitif à grandes cellules B (LMPGCB) En raison d'importants effets secondaires, il n'est utilisé que contre les cas réfractaire au traitement conventionnel, ou en rechute quand le traitement conventionnel a échoué. (fr)
- Аксикабтаген цилолеусел — лекарственный препарат для генной терапии B-крупноклеточной лимфомы. Одобрен для применения: США (2017) (ru)
|
| dbo:alternativeName
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:medlinePlus
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 11747 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:dailymedid
|
- Axicabtagene_ciloleucel (en)
|
| dbp:drugbank
| |
| dbp:kegg
| |
| dbp:legalAu
|
- 4.0 (dbd:nicaraguanCórdoba)
|
| dbp:legalCa
|
- Rx-only / Schedule D (en)
|
| dbp:legalEu
| |
| dbp:legalUk
| |
| dbp:legalUs
| |
| dbp:medlineplus
| |
| dbp:pregnancyAu
| |
| dbp:routesOfAdministration
| |
| dbp:synonyms
| |
| dbp:tradename
| |
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dct:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Axicabtagene ciloleucel, vendu sous le nom de marque Yescarta, est une thérapie (immunothérapie) ciblant deux types de lymphomes : 1.
* lymphome diffus à grandes cellules B (LDGCB) 2.
* lymphome médiastinal primitif à grandes cellules B (LMPGCB) En raison d'importants effets secondaires, il n'est utilisé que contre les cas réfractaire au traitement conventionnel, ou en rechute quand le traitement conventionnel a échoué. (fr)
- Аксикабтаген цилолеусел — лекарственный препарат для генной терапии B-крупноклеточной лимфомы. Одобрен для применения: США (2017) (ru)
- Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment. T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor. The resulting chimeric antigen receptor T cells (CAR-Ts) that react to the cancer are then given back to the person to populate the bone marrow. Axicabtagene treatment carries a risk for cytokine release syndrome (CRS) and neurological toxicities. (en)
|
| rdfs:label
|
- Axicabtagene ciloleucel (en)
- Axicabtagene ciloleucel (fr)
- Axicabtagene ciloleucel (ru)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
